Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

GENEBRA--(BUSINESS WIRE)--Oral-B, marca de escovas de dentes nº 1 usada e recomendada por dentistas em todo o mundo, anunciou hoje novas evidências que reforçam a superioridade da tecnologia Oral-B iO. Em uma meta-análise de rede independente, revisada por pares e publicada em 2026, que abrangeu 19 estudos clínicos randomizados com mais de 1.300 participantes, a tecnologia oscilatória-rotatória da Oral-B iO foi classificada em primeiro lugar na remoção de placa bacteriana e na redução da gengiv...

GINEVRA--(BUSINESS WIRE)--Oral-B, il 1º marchio di spazzolini utilizzato e consigliato dai dentisti di tutto il mondo, ha annunciato oggi la pubblicazione di nuove prove che ribadiscono la superiorità della tecnologia Oral-B iO. In una meta-analisi di rete indipendente condotta nel 2026 e sottoposta a revisione tra pari di 19 studi clinici randomizzati che ha coinvolto più di 1.300 partecipanti, la tecnologia di roto-oscillazione alla base di Oral-B iO si è classificata al 1º posto per la rimoz...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LIVINGSTON, N.J.--(BUSINESS WIRE)--CoreWeave, Inc. (Nasdaq: CRWV) (“CoreWeave”) today announced its intention to offer, subject to market and other conditions, $3.0 billion aggregate principal amount of its convertible senior notes due 2033 (the “Notes”) in a private offering. CoreWeave also intends to grant the initial purchasers of the Notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an addition...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

GENÈVE--(BUSINESS WIRE)--Oral-B, het tandenborstelmerk dat wereldwijd het meest door tandartsen wordt gebruikt en aanbevolen, heeft vandaag nieuwe bewijzen gepresenteerd die de superieure werking van de Oral-B iO-technologie onderstrepen. Uit een onafhankelijke, door vakgenoten beoordeelde netwerk-meta-analyse van 19 gerandomiseerde klinische studies met meer dan 1.300 deelnemers, kwam de oscillerend-roterende technologie van de Oral-B iO naar voren als de nummer 1 voor het verwijderen van tand...

BOSTON--(BUSINESS WIRE)--New research from Fidelity Investments® finds that having a plan on paper doesn’t necessarily leave families feeling prepared for the future. According to the 2026 Transition Ready Family study1, many older adults have taken important planning steps, yet only 37% say they have strong peace of mind about their future plans, and more than half of those who have completed plans still lack confidence. Building on previous findings that validated peace of mind as a top plann...

WINNIPEG, Manitoba--(BUSINESS WIRE)--EIC announces September 2026 Dividend...

TORONTO--(BUSINESS WIRE)--Altis Labs, Inc. (“Altis”), the AI endpoint company accelerating clinical trials, today announced findings from an independent post-hoc analysis evaluating its AI-powered imaging endpoint, IPRO, in the MARIPOSA Phase 3 trial.1 The findings, which were presented at the World Conference on Lung Cancer (WCLC) 2026 in Seoul, Republic of Korea, show that Altis’ IPRO Response Rate detected an early, notable treatment effect, while RECIST-based objective response rate (ORR) f...